Federal Register / Vol. 75, No. 236 / Thursday, December 9, 2010 / Notices 76755 

addition, Defendants will abate leadbased paint hazards on friction and 

impact surfaces, stabilize other leadbased paint hazards, and pay an 

administrative penalty of $7,500. 

The Department of Justice will receive 

for a period of thirty (30) days from the 

date of this publication comments 

relating to the Proposed Consent Decree. 

Comments should be addressed to the 

Assistant Attorney General, 

Environment and Natural Resources 

Division, and either e-mailed to 

pubcomment-ees.enrd@usdoj.gov or 

mailed to U.S. Department of Justice, 

Washington, DC 20044–7611 P.O. Box 

7611, U.S. Department of Justice, 

Washington, DC 20044–7611, and 

should refer to United States v. 

Combined Development Co. I, LLC, et 

al., D.J. Ref. # 90–5–1–1–09435. 

The Proposed Consent Decree may be 

examined at the Department of Housing 

and Urban Development, Office of 

General Counsel, 451 7th St. NW., Room 

9262, Washington, DC 20410; at the 

office of the United States Attorney for 

the Southern District of Ohio, 303 

Marconi Blvd., Suite 200, Columbus, 

Ohio 43215 (Attn. Assistant United 

States Attorney Andrew M. Malek); and 

at U.S. EPA Region 5, 77 W. Jackson 

Blvd., Chicago, IL 60604. During the 

public comment period, the Consent 

Decree may also be examined on the 

following Department of Justice Web 

site, to http://www.usdoj.gov/enrd/ 

Consent_Decrees.html. A copy of the 

Consent Decree may also be obtained by 

mail from the Consent Decree Library, 

P.O. Box 7611, U.S. Department of 

Justice, Washington, DC 20044–7611 or 

by faxing or e-mailing a request to Tonia 

Fleetwood (tonia.fleetwood@usdoj.gov), 

fax no. (202) 514–0097, phone 

confirmation number (202) 514–1547. In 

requesting a copy from the Consent 

Decree Library, please enclose a check 

in the amount of $9.25 (25 cents per 

page reproduction cost) payable to the 

U.S. Treasury or, if by e-mail or fax, 

forward a check in that amount to the 

Consent Decree Library at the stated 

address. 

Maureen Katz, 

Assistant Chief, Environmental Enforcement 

Section, Environment and Natural Resources 

Division. 

[FR Doc. 2010–30900 Filed 12–8–10; 8:45 am] 

BILLING CODE 4410–15–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on October 

19, 2010, Mylan Pharmaceuticals, Inc., 

781 Chestnut Ridge Road, Morgantown, 

West Virginia 26505, made application 

by renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of the basic classes of 

controlled substances listed in schedule 

II: 

Drug Schedule 

Methylphenidate (1724) ................ II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Fentanyl (9801) ............................ II 

The company plans to import the 

listed controlled substances in finished 

dosage form (FDF) from foreign sources 

for analytical testing and clinical trials 

in which the foreign FDF will be 

compared to the company’s own 

domestically-manufactured FDF. This 

analysis is required to allow the 

company to export domesticallymanufactured FDF to foreign markets. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43, 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than January 10, 2011. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

§ 1301.34(b), (c), (d), (e), and (f). As 

noted in a previous notice published in 

the Federal Register on September 23, 

1975, (40 FR 43745–46), all applicants 

for registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: November 29, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30901 Filed 12–8–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated August 3, 2010, and 

published in the Federal Register on 

September 1, 2010, (75 FR 53719), 

Alltech Associates, Inc., 2051 Waukegan 

Road, Deerfield, Illinois 60015, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of the basic 

classes of controlled substances: 

Drug Schedule 

Gamma Hydroxybutyric Acid 

(2010).

I 

Heroin (9200) ............................... I 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Morphine (9300) ........................... II 

The company plans to import these 

controlled substances for the 

manufacture of reference standards. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Alltech Associates, Inc. to import the 

basic classes of controlled substances is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971. DEA 

has investigated Alltech Associates, Inc. 

to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 


erowe on DSK5CLS3C1PROD with NOTICES
76756 Federal Register / Vol. 75, No. 236 / Thursday, December 9, 2010 / Notices 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: November 29, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30897 Filed 12–8–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated July 19, 2010, and 

published in the Federal Register on 

July 28, 2010, (75 FR 44285), Johnson 

Matthey Pharmaceutical Materials, Inc., 

Pharmaceuticals Service, 25 Patton 

Road, Devens, Massachusetts 01434, 

made application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances: 

Drug Schedule 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

Nabilone (7379) ............................ II 

Alfentanil (9737) ........................... II 

Sufentanil (9740) .......................... II 

Remifentanil (9739) ...................... II 

Hydrocodone (9193) ..................... II 

The company plans to utilize this 

facility to manufacture small quantities 

of the listed controlled substances in 

bulk and to conduct analytical testing in 

support of the company’s primary 

manufacturing facility in West Deptford, 

New Jersey. The controlled substances 

manufactured in bulk at this facility will 

be distributed to the company’s 

customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Johnson Matthey Pharmaceutical 

Materials, Inc. to manufacture the listed 

basic classes of controlled substances is 

consistent with the public interest at 

this time. DEA has investigated Johnson 

Matthey Pharmaceutical Materials, Inc. 

to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: November 29, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30904 Filed 12–8–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated March 16, 2010, and 

published in the Federal Register on 

March 24, 2010, (75 FR 14189), Norac 

Inc., 405 S. Motor Avenue, P.O. Box 

577, Azusa, California 91702–3232, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances: 

Drug Schedule 

Gamma Hydroxybutyric Acid 

(2010).

I 

Tetrahydrocannabinols (7370) ..... I 

Methamphetamine (1105) ............ II 

Nabilone (7379) ............................ II 

With regard to Gamma 

Hydroxybutyric Acid (2010), 

Tetrahydrocannabinols (7370), and 

Methamphetamine (1105) only, the 

company manufactures these controlled 

substances in bulk solely for domestic 

distribution within the United States to 

customers engaged in dosage-form 

manufacturing. 

With regard to Nabilone (7379) only, 

the company presently manufactures a 

small amount of this controlled 

substance in bulk solely to conduct 

manufacturing process development 

internally within the company. It is the 

company’s intention that, when the 

manufacturing process is refined to the 

point that its Nabilone bulk product is 

available for commercial use, the 

company will export the controlled 

substance in bulk solely to customers 

engaged in dosage-form manufacturing 

outside the United States. The company 

is aware of the requirement to obtain a 

DEA registration as an exporter to 

conduct this activity. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Norac, Inc. to manufacture the listed 

basic classes of controlled substances is 

consistent with the public interest at 

this time. DEA has investigated Norac, 

Inc. to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: November 29, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30903 Filed 12–8–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated July 23, 2010, and 

published in the Federal Register on 

August 4, 2010, (75 FR 47029), Johnson 

Matthey Pharma Services, 70 Flagship 

Drive, North Andover, Massachusetts 

01845, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the basic classes of 

controlled substances: 

Drug Schedule 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

Hydrocodone (9193) ..................... II 

The company plans to utilize this 

facility to manufacture small quantities 

of the listed controlled substances in 

bulk and to conduct analytical testing in 

support of the company’s primary 

manufacturing facility in West Deptford, 

New Jersey. The controlled substances 

manufactured in bulk at this facility will 

be distributed to the company’s 

customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 


erowe on DSK5CLS3C1PROD with NOTICES